UY31539A1 - Agentes antelminticos y su uso - Google Patents

Agentes antelminticos y su uso

Info

Publication number
UY31539A1
UY31539A1 UY31539A UY31539A UY31539A1 UY 31539 A1 UY31539 A1 UY 31539A1 UY 31539 A UY31539 A UY 31539A UY 31539 A UY31539 A UY 31539A UY 31539 A1 UY31539 A1 UY 31539A1
Authority
UY
Uruguay
Prior art keywords
salts
compounds
agents
antelmintic
treatments
Prior art date
Application number
UY31539A
Other languages
English (en)
Inventor
Thorsten Meyer
Manfred Uphoff
Thomas Simon Ilg
Jirg Schrider
Christophe Pierre Alain Chassaing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31539A1 publication Critical patent/UY31539A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invencion está dirigida a los compuestos y a las sales que son generalmente utiles como agentes antelmínticos, o como intermediarios en los procesos para hacer agentes antelmínticos. Esta invencion también está dirigida a los procesos para hacer los compuestos y las sales, a las composiciones farmacéuticas y a los juegos que comprende los compuestos y las sales, a los usos de los compuestos y las sales para hacer los medicamentos, y a los tratamientos comprendiendo la administracion de los compuestos y las sales a los animales en necesidad de los tratamientos.
UY31539A 2007-12-17 2008-12-17 Agentes antelminticos y su uso UY31539A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1424207P 2007-12-17 2007-12-17
EP08101961 2008-02-25

Publications (1)

Publication Number Publication Date
UY31539A1 true UY31539A1 (es) 2009-08-03

Family

ID=39563449

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31539A UY31539A1 (es) 2007-12-17 2008-12-17 Agentes antelminticos y su uso

Country Status (14)

Country Link
US (1) US8569495B2 (es)
EP (1) EP2234973B1 (es)
CN (1) CN101896459B (es)
AR (1) AR069772A1 (es)
AU (1) AU2008337482B2 (es)
BR (1) BRPI0822033B1 (es)
CA (1) CA2709407A1 (es)
ES (1) ES2501544T3 (es)
NZ (1) NZ586087A (es)
PE (1) PE20091453A1 (es)
TW (1) TW200938203A (es)
UY (1) UY31539A1 (es)
WO (1) WO2009077527A1 (es)
ZA (1) ZA201004261B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114907A1 (en) 2009-03-31 2010-10-07 Vanderbilt University Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
CA2813189C (en) 2010-09-29 2020-04-28 Sk Biopharmaceuticals Co., Ltd. Novel methylcyclohexane derivatives and uses thereof
EP2468096A1 (en) 2010-12-21 2012-06-27 Intervet International BV Anthelmintic combinations
WO2014081697A2 (en) * 2012-11-20 2014-05-30 Merial Limited Anthelmintic compounds and compositions and method of using thereof
FR3000065A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
EP3145925B1 (en) 2014-05-19 2020-11-04 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds
WO2016005577A1 (en) * 2014-07-11 2016-01-14 Intervet International B.V. Use of anthelmintic agents against dirofilaria immitis
EP3177291A1 (en) * 2014-07-11 2017-06-14 Intervet International B.V. Use of anthelmintic agents against dirofilaria immitis
US10597364B2 (en) 2015-01-20 2020-03-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
CA3026982A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
AU2018240172C1 (en) 2017-03-20 2019-10-24 Novo Nordisk Health Care Ag Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
CN107987012A (zh) * 2018-01-29 2018-05-04 田元强 一种4-苄基哌啶类酰胺化合物及其在防治植物线虫病害中的应用
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819681A (en) * 1957-01-24 1959-09-09 Wellcome Found Improvements in and relating to quaternary ammonium compounds and the preparation thereof
GB1032251A (en) * 1961-06-22 1966-06-08 Wellcome Found Piperazine compounds and their preparation
CH542828A (de) * 1970-09-02 1973-10-15 Agripat Sa Verfahren zur Herstellung neuer Thioharnstoffe
US4247710A (en) * 1978-02-08 1981-01-27 Hoffmann-La Roche Inc. Intermediate in the production of adrenergic blocking agents
DE19529604A1 (de) * 1995-08-11 1997-02-13 Bayer Ag Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
WO2000035877A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
CN101896459B (zh) 2013-07-24
ES2501544T3 (es) 2014-10-02
ZA201004261B (en) 2011-02-23
NZ586087A (en) 2011-08-26
AU2008337482B2 (en) 2013-09-12
EP2234973B1 (en) 2014-07-02
CA2709407A1 (en) 2009-06-25
AU2008337482A1 (en) 2009-06-25
BRPI0822033A2 (pt) 2015-07-21
CN101896459A (zh) 2010-11-24
WO2009077527A1 (en) 2009-06-25
US20110021506A1 (en) 2011-01-27
AR069772A1 (es) 2010-02-17
PE20091453A1 (es) 2009-10-03
EP2234973A1 (en) 2010-10-06
TW200938203A (en) 2009-09-16
US8569495B2 (en) 2013-10-29
BRPI0822033B1 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
UY31539A1 (es) Agentes antelminticos y su uso
CO2020007218A2 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
UY32502A (es) Agentes antihelmínticos y su utilización
GT200500378A (es) Macrolidos
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600025A (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
UY30282A1 (es) Compuestos quimicos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
HN2010001920A (es) Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa
CO6710926A2 (es) Compuestos de n-heteroarilo
ECSP12011617A (es) Carboxamidas pesticidas
UY30585A1 (es) Derivados de isoserina como inhibidores del factor ixa de la coagulacion
UY31637A1 (es) Farmacoforos duales-antagonistas muscarinicos de pde4
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
PA8661101A1 (es) Compuestos antihelminticos
PA8661601A1 (es) Pirroles sustituidos, composiciones que los contienen, proceso de fabricacion y utilizacion
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
AR051429A1 (es) Composicion farmaceutica ozonizada y metodos para obtenerla
UY31252A1 (es) Derivados de macrolidos utiles en el tratamiento de la malaria

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121123